Words by GOLD newsdesk
A partnership between Sanofi and McLaren Racing aimed at accelerating manufacturing efficiency and performance has been announced by the duo, following a successful pilot in 2021.
The pharma giant and Formula 1 powerhouse will extend their collaboration to enable continued optimisation of Sanofi’s manufacturing operations, enabling its global network to better support the supply of its broad portfolio. This includes the enhanced delivery of its R&D pipeline, with 25 new launches expected in the next five years to meet patients’ needs around the world.
“We are thrilled to partner with McLaren and learn from their winning spirit and culture of going over and above,” said Paul Hudson, Chief Executive Officer, Sanofi. “I see a lot of commonalities in our shared values to stretch, with courage and determination, so we can maximise performance and operational excellence. We want to run our lines with the speed, precision and efficiency of an F1 racing team.”
Indeed, it is hoped that McLaren’s data-driven approach and focus on team high performance will enable Sanofi to adopt a “race-like mindset” and elevate its output by helping to better anticipate and resolve issues before they take place. This will involve the use of modelling simulations of production line changeovers and operations, mirroring McLaren’s use of advanced data analytics and expertise to optimise the high-speed pit stops of F1 races.
Zak Brown, Chief Executive Officer, McLaren Racing, added: “It is important that two global companies who share values work together to maximise performance. We look forward to continuing to collaborate with Sanofi to make a positive impact not only in manufacturing but to help Sanofi improve patients’ lives.”